1. Effects of a novel NADPH oxidase inhibitor (S42909) on wound healing in an experimental ischemic excisional skin model.
- Author
-
Sotomayor S, Pascual G, Blanc-Guillemaud V, Mesa-Ciller C, García-Honduvilla N, Cifuentes A, and Buján J
- Subjects
- Animals, Collagen Type I metabolism, Collagen Type III metabolism, Gene Expression drug effects, Inflammation genetics, Inflammation prevention & control, Interferon-gamma genetics, Interleukin-10 genetics, Ischemia complications, Male, Neovascularization, Physiologic, Rabbits, Skin Ulcer drug therapy, Skin Ulcer etiology, Skin Ulcer genetics, Transforming Growth Factor beta1 genetics, Transforming Growth Factor beta1 metabolism, Vascular Endothelial Growth Factor A metabolism, NADPH Oxidases antagonists & inhibitors, RNA, Messenger metabolism, Re-Epithelialization drug effects, Skin Ulcer metabolism
- Abstract
Chronic wounds are a serious healthcare problem. As non-healing wounds involve continuous pathologic inflammatory stage, research is focused on anti-inflammatory treatments. Our objective was to analyze the effect of S42909, a potent NADPH oxidase inhibitor activity, with vascular anti-inflammatory properties. An ischemic rabbit ear ulcer model (24 New Zealand white rabbits) was used to evaluate the reepithelialization/contraction areas, anti-/pro-inflammatory cytokines mRNA (TGF-β1/IL-10/IFN-γ/VEGF) by qRT-PCR, collagen I/III deposition, and neovascularization (TGF-β1/VEGF) by morphological and immunohistochemical analyses. Three different doses were administered by gavage for 2 weeks: 10 and 30 mg/kg/d in self-microemulsion drug delivery system (SMEDDS) and 100 mg/kg/d in arabic gum. Each vehicle was used as control. No signs of infection or necrosis were found. Reepithelialization was almost complete whatever the groups reaching 95% at the dose of 100 mg/kg. Wound contraction was significantly reduced in all S42909-treated groups. A significant increase in anti-inflammatory cytokines TGF-β1 mRNA and IL-10 mRNA was observed at the dose of 100 and 30 mg/kg/d, respectively. No changes were observed in pro-inflammatory factors INF-γ and VEGF mRNA. Ischemic skin wound areas had scarce expression of collagen I/III and showed rich glycosaminoglycans content. Treatment increased the collagen deposition and TGF-β1 protein expression and decreased glycosaminoglycan content dose dependently; however, no effect in VEGF was appreciated. Therefore, our results indicate that S42909 improved healing process by dampening excessive inflammation and facilitating collagen deposition without wound contraction phenomena. S42909 might be a promising therapy to treat chronic wounds as venous leg ulcers., (© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF